Know Cancer

or
forgot password


Phase 3
6 Months
21 Years
Not Enrolling
Both
Rhabdomyosarcoma, Malignant Soft Tissue

Thank you

Trial Information


Inclusion Criteria:



- age > 6 months and < 18 years

- no distant metastases

- diagnosis within previous 8 weeks without prior treatment except surgery

- pathology available for central review

- written consent according to institutional requirement

Exclusion Criteria:

- stage III (node positive)

- stage I or II non alveolar orbital tumours

- patients with parameningeal disease aged < 3 years

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To explore survival advantage for an intensified chemotherapy strategy in a randomised trial

Principal Investigator

Odile OBERLIN, Dr

Investigator Role:

Principal Investigator

Investigator Affiliation:

Gustave Roussy, Cancer Campus, Grand Paris

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

RMS95

NCT ID:

NCT00162695

Start Date:

July 1995

Completion Date:

Related Keywords:

  • Rhabdomyosarcoma
  • Malignant Soft Tissue
  • Rhabdomyosarcoma
  • Sarcoma

Name

Location